Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 104, Issue 22, Pages 1712-1723
Publisher
Oxford University Press (OUP)
Online
2012-10-29
DOI
10.1093/jnci/djs395
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer
- (2012) Peng Guan et al. INTERNATIONAL JOURNAL OF CANCER
- Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine
- (2012) Cecilia M. Roteli-Martins et al. Human Vaccines & Immunotherapeutics
- Cost-effectiveness of different human papillomavirus vaccines in Singapore
- (2011) Vernon J Lee et al. BMC PUBLIC HEALTH
- Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles
- (2011) S. Capri et al. GYNECOLOGIC ONCOLOGY
- The known unknowns of HPV natural history
- (2011) Patti E. Gravitt JOURNAL OF CLINICAL INVESTIGATION
- Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada
- (2011) François Coutlée et al. JOURNAL OF MEDICAL VIROLOGY
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Cosette M Wheeler et al. LANCET ONCOLOGY
- Modelling the Epidemiology of Infectious Diseases for Decision Analysis
- (2011) Mark Jit et al. PHARMACOECONOMICS
- The Impact of Anogenital Warts on Health-Related Quality of Life: A 6-Month Prospective Study
- (2011) Mélanie Drolet et al. SEXUALLY TRANSMITTED DISEASES
- The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme
- (2011) T. R. H. Read et al. SEXUALLY TRANSMITTED INFECTIONS
- The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia
- (2011) Megan A. Smith et al. VACCINE
- Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication
- (2010) Ni Li et al. INTERNATIONAL JOURNAL OF CANCER
- Cervical Human Papillomavirus Prevalence in 5 Continents: Meta‐Analysis of 1 Million Women with Normal Cytological Findings
- (2010) Laia Bruni et al. JOURNAL OF INFECTIOUS DISEASES
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
- (2010) Silvia de Sanjose et al. LANCET ONCOLOGY
- Liquid Compared With Conventional Cervical Cytology
- (2010) Marc Arbyn et al. OBSTETRICS AND GYNECOLOGY
- Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis
- (2010) Nicolas Van de Velde et al. VACCINE
- Colposcopy to evaluate abnormal cervical cytology in 2008
- (2009) Dana M. Chase et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- A cost–utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme
- (2009) Anne Dee et al. EUROPEAN JOURNAL OF PUBLIC HEALTH
- Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆
- (2009) Marie-Pierre David et al. GYNECOLOGIC ONCOLOGY
- Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine
- (2009) Suzanne M. Garland et al. JOURNAL OF INFECTIOUS DISEASES
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years
- (2009) Cosette M. Wheeler et al. JOURNAL OF INFECTIOUS DISEASES
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years
- (2009) Darron R. Brown et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- A review of human carcinogens—Part B: biological agents
- (2009) Véronique Bouvard et al. LANCET ONCOLOGY
- Estimating Progression Rates for Human Papillomavirus Infection From Epidemiological Data
- (2009) Mark Jit et al. MEDICAL DECISION MAKING
- Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries
- (2009) Marc Brisson et al. Public Health Genomics
- Systematic review of human papillomavirus prevalence in invasive penile cancer
- (2008) Danielle M. Backes et al. CANCER CAUSES & CONTROL
- Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia
- (2008) Steven Ades et al. INTERNATIONAL JOURNAL OF CANCER
- Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis
- (2008) Hugo De Vuyst et al. INTERNATIONAL JOURNAL OF CANCER
- Health and Economic Implications of HPV Vaccination in the United States
- (2008) Jane J. Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modeling Cervical Cancer Prevention in Developed Countries
- (2008) Jane J. Kim et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now